Biocon's contract research arm Syngene International today reported a 19.6 per cent rise in standalone net profit at Rs 66.5 crore for March quarter.
It had posted a net profit of Rs 55.6 crore in the corresponding period of the previous fiscal, Syngene International said in a BSE filing.
"This growth has been driven by robust performances within all three of our key business verticals; dedicated R&D centres, discovery services as well as development and manufacturing services," Syngene International CEO Jonathan Hunt said.
Standalone total income from operations also rose to Rs 331.5 crore for the quarter under review as against Rs 251.8 crore in the same period a year ago.
For the entire fiscal, the company posted a net profit of Rs 221.2 crore compared with Rs 175 crore in 2014-15.
Total income from operations stood at Rs 1,107 crore in 2015-16 fiscal as against Rs 859.9 crore in the previous year.
Syngene International stock today closed 1.95 per cent up at Rs 378.55 on BSE.
